SN-38 O-beta-D-glucuronide (BioDeep_00000902615)
代谢物信息卡片
SN-38 O-beta-D-glucuronide
化学式: C28H27N2O11- (567.1614772)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC6C(C(C(C(O6)C(=O)[O-])O)O)O
InChI: InChI=1S/C28H28N2O11/c1-3-12-13-7-11(40-26-22(33)20(31)21(32)23(41-26)25(35)36)5-6-17(13)29-19-14(12)9-30-18(19)8-16-15(24(30)34)10-39-27(37)28(16,38)4-2/h5-8,20-23,26,31-33,38H,3-4,9-10H2,1-2H3,(H,35,36)/p-1/t20-,21-,22+,23-,26+,28-/m0/s1
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Shaun D Fontaine, Angelo D Santi, Ralph Reid, Philip C Smith, Gary W Ashley, Daniel V Santi. PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity.
Cancer chemotherapy and pharmacology.
2020 01; 85(1):225-229. doi:
10.1007/s00280-019-03987-z. [PMID: 31707444] - Alexander K Berg, Jan C Buckner, Evanthia Galanis, Kurt A Jaeckle, Matthew M Ames, Joel M Reid. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.
Journal of clinical pharmacology.
2015 Nov; 55(11):1303-12. doi:
10.1002/jcph.543. [PMID: 25975718] - Pankajini Mallick, Pranav Shah, Adarsh Gandhi, Romi Ghose. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Life sciences.
2015 Oct; 139(?):132-8. doi:
10.1016/j.lfs.2015.08.017. [PMID: 26334566] - Kouichi Hirose, Koushiro Yamashita, Hirofumi Takada, Noriko Kaneda, Kohei Fukami, Eiji Maruo, Mizuho Kitamura, Junichi Hasegawa, Yorinobu Maeda. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
International journal of clinical oncology.
2014 Apr; 19(2):397-402. doi:
10.1007/s10147-013-0558-1. [PMID: 23605141] - B Valenzuela Jiménez, M González Sales, V Escudero Ortiz, E Martínez Navarro, C Pérez Ruixo, J Rebollo Liceaga, R González Manzano, J J Pérez Ruixo. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.
2013 Mar; 37(2):111-27. doi:
10.7399/fh.2013.37.2.386. [PMID: 23789755] - Tomoharu Yokooji, Yoshihiro Kawabe, Nobuhiro Mori, Teruo Murakami. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
The Journal of pharmacy and pharmacology.
2013 Feb; 65(2):280-91. doi:
10.1111/j.2042-7158.2012.01592.x. [PMID: 23278696] - P-T Huang, K-C Chen, Z M Prijovich, T-L Cheng, Y-L Leu, S R Roffler. Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.
Cancer gene therapy.
2011 Jun; 18(6):381-9. doi:
10.1038/cgt.2011.3. [PMID: 21350582] - Wei Zhang, Ginger E Dutschman, Xin Li, Min Ye, Yung-Chi Cheng. Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Oct; 877(27):3038-44. doi:
10.1016/j.jchromb.2009.07.025. [PMID: 19648066] - Hiroyuki Tanaka, Katsuhiko Saito, Kozo Mino, Keishiro Izumi, Masao Harada, Hiroshi Isobe. [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
Gan to kagaku ryoho. Cancer & chemotherapy.
2009 Sep; 36(9):1505-9. doi:
. [PMID: 19755821] - Zeljko M Prijovich, Kai-Chuan Chen, Steve R Roffler. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
Molecular cancer therapeutics.
2009 Apr; 8(4):940-6. doi:
10.1158/1535-7163.mct-08-0812. [PMID: 19372567] - David Czock, Franz Maximilian Rasche, Benjamin Boesler, Maria Shipkova, Frieder Keller. Irinotecan in cancer patients with end-stage renal failure.
The Annals of pharmacotherapy.
2009 Feb; 43(2):363-9. doi:
10.1345/aph.1l511. [PMID: 19193575] - Patrick A Thompson, Manish Gupta, Gary L Rosner, Alexander Yu, Jeffrey Barrett, Lisa Bomgaars, Mark L Bernstein, Susan M Blaney, John Mondick. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Cancer chemotherapy and pharmacology.
2008 Nov; 62(6):1027-37. doi:
10.1007/s00280-008-0692-z. [PMID: 18278496] - Floris A de Jong, Jessica M van der Bol, Ron H J Mathijssen, Walter J Loos, Ron A A Mathôt, Jos J E M Kitzen, Martin J van den Bent, Jaap Verweij. Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.
Cancer biology & therapy.
2007 Sep; 6(9):1368-74. doi:
10.4161/cbt.6.9.4567. [PMID: 17873515] - Milind M Javle, Shousong Cao, Farukh A Durrani, Lakshmi Pendyala, David D Lawrence, Patrick F Smith, Patrick J Creaven, Diane C Noel, Renuka V Iyer, Youcef M Rustum. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007 Feb; 13(3):965-71. doi:
10.1158/1078-0432.ccr-06-0551. [PMID: 17289892] - Peter J Tobin, Philip Beale, Leesa Noney, Sandy Liddell, Laurent P Rivory, Stephen Clarke. A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.
Cancer chemotherapy and pharmacology.
2006 Feb; 57(3):309-16. doi:
10.1007/s00280-005-0053-0. [PMID: 16003560] - Floris A de Jong, Ron H J Mathijssen, Rujia Xie, Jaap Verweij, Alex Sparreboom. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2004 Jun; 10(12 Pt 1):4068-71. doi:
10.1158/1078-0432.ccr-03-0591. [PMID: 15217940] - Sylvain Poujol, Frédéric Pinguet, Françoise Malosse, Cécile Astre, Marc Ychou, Stéphane Culine, Françoise Bressolle. Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.
Clinical chemistry.
2003 Nov; 49(11):1900-8. doi:
10.1373/clinchem.2003.023481. [PMID: 14578322] - Cheri Enders Klein, Elora Gupta, Joel M Reid, Pamela J Atherton, Jeff A Sloan, Henry C Pitot, Mark J Ratain, Helen Kastrissios. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Clinical pharmacology and therapeutics.
2002 Dec; 72(6):638-47. doi:
10.1067/mcp.2002.129502. [PMID: 12496745] - Jean-François Gagné, Valerie Montminy, Patrick Belanger, Kim Journault, Genevieve Gaucher, Chantal Guillemette. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
Molecular pharmacology.
2002 Sep; 62(3):608-17. doi:
10.1124/mol.62.3.608. [PMID: 12181437] - Rujia Xie, Ron H J Mathijssen, Alex Sparreboom, Jaap Verweij, Mats O Karlsson. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Clinical pharmacology and therapeutics.
2002 Sep; 72(3):265-75. doi:
10.1067/mcp.2002.126741. [PMID: 12235447] - J A Sloan, P Atherton, J Reid, H C Pitot, C Erlichman, L Schaaf. Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.
Cancer chemotherapy and pharmacology.
2001 Sep; 48(3):241-9. doi:
10.1007/s002800100296. [PMID: 11592347] - Y Machida, H Onishi, A Kurita, H Hata, A Morikawa, Y Machida. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
Journal of controlled release : official journal of the Controlled Release Society.
2000 May; 66(2-3):159-75. doi:
10.1016/s0168-3659(99)00267-9. [PMID: 10742577] - A Kurita, S Kado, N Kaneda, M Onoue, S Hashimoto, T Yokokura. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
Cancer chemotherapy and pharmacology.
2000; 46(3):211-20. doi:
10.1007/s002800000151. [PMID: 11021738] - E Wasserman, C Cuvier, F Lokiec, F Goldwasser, S Kalla, D Méry-Mignard, M Ouldkaci, A Besmaine, G Dupont-André, M Mahjoubi, M Marty, J L Misset, E Cvitkovic. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1999 Jun; 17(6):1751-9. doi:
10.1200/jco.1999.17.6.1751. [PMID: 10561212] - A Sparreboom, P de Bruijn, M J de Jonge, W J Loos, G Stoter, J Verweij, K Nooter. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.
Journal of chromatography. B, Biomedical sciences and applications.
1998 Aug; 712(1-2):225-35. doi:
10.1016/s0378-4347(98)00147-9. [PMID: 9698245] - L P Rivory, M C Haaz, P Canal, F Lokiec, J P Armand, J Robert. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1997 Aug; 3(8):1261-6. doi:
NULL. [PMID: 9815808]